Study to Assess SLN124 in Patients With Polycythemia Vera
← catalyst calendarNCT05499013 · readout ≤ 42 d
Sponsored by Silence Therapeutics plc (industry) · SLN — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
69actual
Sites
28
Countries
Australia, Bulgaria, Canada +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-26 | actual | When the study began enrolling |
| Primary completion | Sep 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2022-08-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Polycythemia Vera
Interventions
- Drug: SLN124
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPhase 1: Incidence of treatment-emergent adverse events (AEs)
measured Day 239
Phase 1: Assessment of the number of phlebotomies at intervals
measured 6 months prior to dosing to Day 239
Phase 2: Proportion of patients who achieve response between week 18 and week 36 (placebo controlled double blind phase)
measured 18 to 36 weeks
Permalink · SLN's whole pipeline · Catalyst calendar · Every registered study · What changed